inclusion criteria: 1. male or female patient of ≥ 18 years of age, regardless of vaccine status or viral variant or underlying medical conditions, willing and able to provide written informed consent for participation in the study and ready to comply with the study procedures and schedule. 2. patient having a positive diagnosis for the presence of sars-cov-2, obtained from a recently performed rrt-pcr (≤ 3 days) with any 1 of the following: i. ct value ≤ 25 ii. hospitalized for having classical (cdc defined) symptoms of covid-19 (onset ≤ 5 days) iii. high risk category of covid-19: blood group type a-positive type 2 diabetes, or other chronic disease known to have higher morbidity risk with sars-cov-2 infection. 3. patient has the ability to take oral medication and be willing to adhere to the trial protocol regimen of repeated swab collections and frequent follow up for 29 days. 4. females of child bearing potential who has been using a highly effective contraception for at least 1 month prior to screening and agrees to continue using it during the study participation/enrolment, confirmed through negative pregnancy test

inclusion criteria: 1. male or female patient of ≥ 18 years of age, regardless of vaccine status or viral variant or underlying medical conditions, willing and able to provide written informed consent for participation in the study and ready to comply with the study procedures and schedule. 2. patient having a positive diagnosis for the presence of sars-cov-2, obtained from a recently performed rrt-pcr (≤ 3 days) with any 1 of the following: i. ct value ≤ 25 ii. hospitalized for having classical (cdc defined) symptoms of covid-19 (onset ≤ 5 days) iii. high risk category of covid-19: blood group type a-positive type 2 diabetes, or other chronic disease known to have higher morbidity risk with sars-cov-2 infection. 3. patient has the ability to take oral medication and be willing to adhere to the trial protocol regimen of repeated swab collections and frequent follow up for 29 days. 4. females of child bearing potential who has been using a highly effective contraception for at least 1 month prior to screening and agrees to continue using it during the study participation/enrolment, confirmed through negative pregnancy test

inclusion criteria: male or female patient of ≥ 18 years of age, regardless of vaccine status or viral variant or underlying medical conditions, willing and able to provide written informed consent for participation in the study and ready to comply with the study procedures and schedule. patient having a positive diagnosis for the presence of sars-cov-2, obtained from a recently performed rrt-pcr (≤ 3 days) with any 1 of the following: i. ct value ≤ 25 ii. hospitalized for having classical (cdc defined) symptoms of covid-19 (onset ≤ 5 days) iii. high risk category of covid-19: blood group type a-positive type 2 diabetes, or other chronic disease known to have higher morbidity risk with sars-cov-2 infection. patient has the ability to take oral medication and be willing to adhere to the trial protocol regimen of repeated swab collections and frequent follow up for 29 days. females of child bearing potential who has been using a highly effective contraception for at least 1 month prior to screening and agrees to continue using it during the study participation/enrolment, confirmed through negative pregnancy test

inclusion criteria: male or female patient of ≥ 18 years of age, regardless of vaccine status or viral variant or underlying medical conditions, willing and able to provide written informed consent for participation in the study and ready to comply with the study procedures and schedule. patient having a positive diagnosis for the presence of sars-cov-2, obtained from a recently performed rrt-pcr (≤ 3 days) with any 1 of the following: i. ct value ≤ 25 ii. hospitalized for having classical (cdc defined) symptoms of covid-19 (onset ≤ 5 days) iii. high risk category of covid-19: blood group type a-positive type 2 diabetes, or other chronic disease known to have higher morbidity risk with sars-cov-2 infection. patient has the ability to take oral medication and be willing to adhere to the trial protocol regimen of repeated swab collections and frequent follow up for 29 days. females of child bearing potential who has been using a highly effective contraception for at least 1 month prior to screening and agrees to continue using it during the study participation/enrolment, confirmed through negative pregnancy test

inclusion criteria: - 1. male or female patient of ≥ 18 years of age, willing and able to provide written informed consent for participation in the study and ready to comply with the study procedures and schedule. 2. patient having a positive diagnosis for presence of sars-cov-2, obtained from a recently performed rrt-pcr (≤ 3 days) with any 1 of the following: i. ct value ≤ 25 ii. hospitalized for having classical (cdc defined) symptoms of covid-19 (onset ≤ 5 days) iii. high risk category of covid-19: blood group type a-positive type 2 diabetes, or other chronic disease known to have higher morbidity risk with sars-cov-2 infection. 3. patient has the ability to take oral medication and be willing to adhere to the trial protocol regimen of repeated swab collections and frequent follow up for 29 days. 4. females of child bearing potential who has been using a highly effective contraception for at least 1 month prior to screening and agrees to continue using it during the study participation/enrolment, confirmed through negative pregnancy test

inclusion criteria: - 1. male or female patient of ≥ 18 years of age, willing and able to provide written informed consent for participation in the study and ready to comply with the study procedures and schedule. 2. patient having a positive diagnosis for presence of sars-cov-2, obtained from a recently performed rrt-pcr (≤ 3 days) with any 1 of the following: i. ct value ≤ 25 ii. hospitalized for having classical (cdc defined) symptoms of covid-19 (onset ≤ 5 days) iii. high risk category of covid-19: blood group type a-positive type 2 diabetes, or other chronic disease known to have higher morbidity risk with sars-cov-2 infection. 3. patient has the ability to take oral medication and be willing to adhere to the trial protocol regimen of repeated swab collections and frequent follow up for 29 days. 4. females of child bearing potential who has been using a highly effective contraception for at least 1 month prior to screening and agrees to continue using it during the study participation/enrolment, confirmed through negative pregnancy test